Skip to content

INTERPACE BIOSCIENCES, INC.

IDXG · OTCM

CIK 1054102fmd_05W3P5J9SK5MXN1E9F2XJ6VK8BManufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard

Coverage: Jan 01, 2010 to Jun 30, 2026, 65 periods

Income Statement · Annual · Millions · USD
Line itemFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Total revenues13162224323332404739
Cost of revenue771016221414151715
Net interest income–––––(0)(0)(0)––
Gross profit69128111918253024
Research and development2123311111
Selling, general and administrative16161725272020202119
Compensation and benefits––––––––––
Total operating expenses13152435372522212220
Operating income(6)(6)(13)(26)(26)(6)(4)484
Interest expense20001–––––
Other non-operating income (expense)0(2)000(0)(1)(1)––
Income before taxes(9)(13)(13)(27)(26)(8)(6)274
Income tax expense(0)(0)0(0)0(1)000(21)
Net income from continuing operations(8)(13)(13)(27)(26)(7)(6)2725
Net income(22)13(13)(27)(26)(15)(22)2725
Net income to common shareholders––(13)(27)(29)(15)–2625
INTERPACE BIOSCIENCES, INC. (IDXG) financial statements · FinancialMD